Michael Watson, DO
Family Medicine · Corvallis, ORNPI 1316366677
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.8% of the total across 313 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 26 manufacturers reported payments, led by AbbVie at 25.1% of the total. Among family medicine clinicians in OR with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 313 payments — averaging $14.69 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1K
- Pfizer$572
- Novo Nordisk$543
- AstraZeneca$484
- Axsome Therapeutics, Inc.$252
- Boehringer Ingelheim$247
- plus $1K from 20 others
What the payments were for
- Food & beverage$4,590100%
- Education$70%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 97 | $1,153 |
| Pfizer | 43 | $572 |
| Novo Nordisk | 36 | $543 |
| AstraZeneca | 26 | $484 |
| Axsome Therapeutics, Inc. | 11 | $252 |
| Boehringer Ingelheim | 18 | $247 |
| GSK | 10 | $168 |
| Lilly USA, LLC | 10 | $164 |
| Novartis | 9 | $159 |
| Amgen | 10 | $159 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 7 | $106 |
| Astellas Pharma US Inc | 5 | $81 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 4 | $70 |
| Johnson & Johnson | 4 | $69 |
| Biohaven Pharmaceutical Holding Company Ltd. | 4 | $57 |
| Bayer | 3 | $48 |
| Dexcom, Inc. | 3 | $48 |
| Phathom Pharmaceuticals, Inc. | 3 | $46 |
| Medtronic | 2 | $45 |
| Xeris Pharmaceuticals, Inc. | 2 | $31 |
| Siemens Medical Solutions USA, Inc. | 1 | $26 |
| Exact Sciences | 1 | $17 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 1 | $16 |
| Insulet Corporation | 1 | $15 |
| Shire North American Group Inc | 1 | $12 |
| Merck | 1 | $11 |
How this compares
$4,597 in reported general payments places this provider in the 95th percentile of 1,221 family medicine providers in Oregon.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| WakixPitolisant Hcl | 11 | $179,230 |
| MounjaroTirzepatide | 96 | $123,445 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 114 | $81,544 |
| JardianceEmpagliflozin | 81 | $76,468 |
| OzempicSemaglutide | 67 | $63,536 |
| EliquisApixaban | 71 | $50,029 |
| FarxigaDapagliflozin Propanediol | 73 | $48,890 |
| RybelsusSemaglutide | 38 | $36,448 |
| Tresiba Flextouch U-200Insulin Degludec | 35 | $34,107 |
| TrulicityDulaglutide | 31 | $33,410 |
| JanuviaSitagliptin Phosphate | 30 | $25,768 |
| VraylarCariprazine Hcl | 15 | $20,765 |
| EntrestoSacubitril/Valsartan | 12 | $18,474 |
| LinzessLinaclotide | 31 | $17,277 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 17 | $10,738 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity | $164 | $156,855127 claims |
| Novo NordiskOzempic, Rybelsus | $543 | $99,984105 claims |
| GSKTrelegy Ellipta | $168 | $81,544114 claims |
| Boehringer IngelheimJardiance | $247 | $76,46881 claims |
| AstraZenecaFarxiga, Breztri Aerosphere | $484 | $59,62890 claims |
| PfizerEliquis | $572 | $50,02971 claims |
| AbbVieVraylar, Linzess | $1,153 | $38,04346 claims |
| MerckJanuvia | $11 | $25,76830 claims |
| NovartisEntresto | $159 | $18,47412 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,221 family medicine providers in Oregon.
Other family medicine in Corvallis
- David LeeCorvallis$10K
- Eden MillerBend$1.7M
- Anil RajaniHood River$325K
- Stephen NelsonMedford$101K
- Karen KahnAshland$86K
- Robert GobboPortland$53K
- Kevin MillerSisters$39K
- Morris MaizelsCentral Point$25K
- Maureen MaysPortland$24K
- Nathaniel FondellMedford$21K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.